Clinical trial · Interventional
Conventional Versus Elastography Targeted Endoscopic Ultrasound Fine Needle Aspiration of Solid Pancreatic Lesions
Conventional Versus Elastography Targeted Endoscopic Ultrasound Fine Needle Aspiration of Solid Pancreatic Lesions: a Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Diagnostic assessment of solid pancreatic lesions may represent a real challenge in the clinical practice, even with the aid of tissue sampling by means of endoscopic ultrasound (EUS) fine needle aspiration (FNA). Aim of this randomized controlled trial (RCT) is to establish the diagnostic accuracy, sensitivity, and specificity of real time elastography (RTE)-guided EUS-FNA as compared to conventional EUS-FNA in a series of patients with solid pancreatic masses. Eligible will be patients with solid pancreatic masses detected at abdominal imaging (ultrasound, CT-scan or MRI). In the treatment arm, RTE assessment of pancreatic masses will be performed using a last generation ultrasound machine, and all suspicious areas at elastography (i.e. those appearing in dark blue color as a consequence of higher cellularity of tumoral tissue) will be recorded and stored in our database. A 25 G needle will be then inserted into the most suspicious part ("dark blue") of the lesion and immediately after the procedure the stylet will be removed. At the end of the procedure, the needle will be retracted and the samples will be prepared for cytological examination. Primary endpoint will be diagnostic yield of the procedure. Secondary endpoints the diagnostic sensitivity, specificity, number of passes needed to achieve an adequate sample and safety It will be planned to enroll 142 patients (71 per arms) within 1 year. A minimum follow up of 6 months from the last patient unsuitable to surgery will be required.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conventional EUS-FNA | Device | — | UNRESOLVED |
| RTE-guided EUS-FNA | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- RTE-guided EUS-FNA
- description
- The needle will be then inserted into the most suspicious part ("dark blue") of the lesion as assessed at real time elastography.
- interventionNames
- Device: RTE-guided EUS-FNA
- type
- ACTIVE_COMPARATOR
- label
- Conventional EUS-FNA
- description
- A 25 G needle with a central stylet to protect the aspiration channel of the needle will be introduced though the endoscope's working channel.
- interventionNames
- Device: Conventional EUS-FNA
Primary outcomes (1)
- measure
- Diagnostic accuracy
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with solid pancreatic masses detected at abdominal imaging (ultrasound, CT-scan or MRI). Exclusion Criteria: * Age under 18 years * Cystic pancreatic lesions * Lesions \< 1 cm * History of previous gastrectomy * Patients with severe coagulopathy or under anticoagulant/antiaggregant therapy which could not be suspended * Refusal to provide informed consent.
References
Publications (0)
Data not yet available